Gliknik Raises $11.5M in Series C Financing
Gliknik Inc., a Baltimore, MD-based immunology company dedicated to patients with cancer and autoimmune disorders, completed an $11.5m Series C financing.
The round was led by First In Ventures (FIV) with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. Kyle Rusconi, a founder of FIV, is joining the Gliknik Board.
Led by CEO David Block, Gliknik is an immunology company creating and advancing biologic drugs for patients with cancer and autoimmune disorders. The company, which has secured $81m to date, intends to use the funds to progress the pipeline of its product candidates, including:
Mersin Elektrik Kesintisi 28 Haziran Pazartesi
mersinhaber.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mersinhaber.com Daily Mail and Mail on Sunday newspapers.
Man wanted in murder of woman killed in her kitchen under arrest in Puerto Rico, Hartford police say Second suspect still on the lam
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.